Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CRNX 
Crinetics Pharmaceuticals Inc (CRNX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/08/2025: CRNX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
17 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $72.67
1 Year Target Price $72.67
| 11 | Strong Buy |
| 5 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 39.91% | Avg. Invested days 53 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/08/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.79B USD | Price to earnings Ratio - | 1Y Target Price 72.67 |
Price to earnings Ratio - | 1Y Target Price 72.67 | ||
Volume (30-day avg) 17 | Beta 0.28 | 52 Weeks Range 24.10 - 62.53 | Updated Date 07/7/2025 |
52 Weeks Range 24.10 - 62.53 | Updated Date 07/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.71 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -30860.11% |
Management Effectiveness
Return on Assets (TTM) -20.13% | Return on Equity (TTM) -30.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1499039577 | Price to Sales(TTM) 3673.25 |
Enterprise Value 1499039577 | Price to Sales(TTM) 3673.25 | ||
Enterprise Value to Revenue 1972.42 | Enterprise Value to EBITDA -13.4 | Shares Outstanding 93680096 | Shares Floating 92278675 |
Shares Outstanding 93680096 | Shares Floating 92278675 | ||
Percent Insiders 2.03 | Percent Institutions 112.39 |
Upturn AI SWOT
Crinetics Pharmaceuticals Inc
Company Overview
History and Background
Crinetics Pharmaceuticals Inc. is a biopharmaceutical company founded in 2008. It focuses on developing novel therapeutics for endocrine diseases and endocrine-related tumors. It went public in 2018. The company has evolved from early research to clinical-stage development, targeting unmet needs in endocrinology.
Core Business Areas
- Drug Development: Focused on creating oral, non-peptide therapeutics for rare endocrine disorders and endocrine-related tumors.
- Clinical Trials: Conducting Phase 1, 2, and 3 clinical trials for various drug candidates.
- Research and Discovery: Engaged in ongoing research to identify and develop new therapeutic targets and drug candidates.
Leadership and Structure
The company is led by CEO Scott Struthers. The organizational structure includes research and development, clinical operations, and commercial teams.
Top Products and Market Share
Key Offerings
- Paltusotine: Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 (SST2) agonist, is Crinetics's leading drug candidate currently in phase III trials for acromegaly. The market share is currently zero because it is not yet FDA approved. Competitors include Novartis (Sandostatin, Pasireotide).
- CRN04894: CRN04894, is an oral ACTH antagonist is in phase II clinical trials for congenital adrenal hyperplasia (CAH). Market share is currently zero, awaiting FDA approval. Competitors include generic hydrocortisone, and newer options from Neurocrine Biosciences.
- CRN04777: CRN04777 is an oral selective nonpeptide somatostatin receptor type 5 (SST5) agonist, is in phase I trials for hyperinsulinism. Market share is currently zero because it is not yet FDA approved. Competitors include diazoxide and surgery.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The endocrine market focuses on hormonal imbalances and related diseases.
Positioning
Crinetics is positioned as a specialized biopharmaceutical company focused on oral, non-peptide therapeutics for endocrine diseases, distinguishing it from companies focusing on injectable therapies.
Total Addressable Market (TAM)
The TAM for endocrine therapies is estimated at billions of dollars annually. Crinetics is targeting specific niches within this large market, particularly rare endocrine disorders, allowing for potentially significant market penetration. Acromegaly market is around $750M, CAH $2.3 Billion
Upturn SWOT Analysis
Strengths
- Novel oral drug candidates
- Strong intellectual property portfolio
- Experienced management team
- Focus on underserved endocrine markets
Weaknesses
- Dependence on clinical trial success
- Limited commercial infrastructure
- High cash burn rate
- Competition from established players
Opportunities
- Successful clinical trial results leading to FDA approval
- Expansion into new endocrine indications
- Strategic partnerships with larger pharmaceutical companies
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other companies developing similar therapies
- Patent challenges
Competitors and Market Share
Key Competitors
- NVS
- SNY
- TEVA
- NBIX
Competitive Landscape
Crinetics has an advantage by developing oral versions of drugs that were previously only available by injection, but it still faces significant competition from larger companies with established products and commercial infrastructure.
Growth Trajectory and Initiatives
Historical Growth: Historically, Crinetics has experienced growth in its pipeline and has secured funding through public offerings and collaborations.
Future Projections: Future growth is contingent on successful clinical trials and FDA approvals. Analyst estimates vary, but generally project significant revenue growth if paltusotine is approved.
Recent Initiatives: Recent initiatives include the advancement of paltusotine into Phase 3 trials and the development of new drug candidates for other endocrine disorders.
Summary
Crinetics Pharmaceuticals is a clinical-stage biopharmaceutical company with potential in the oral endocrine therapeutics market. Success hinges heavily on the outcomes of its ongoing clinical trials, particularly paltusotine. While it has a strong IP portfolio and is tackling underserved markets, it faces risks associated with clinical development and competition. Future success requires favorable trial data and successful navigation of regulatory hurdles.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Crinetics Pharmaceuticals Inc. Investor Relations
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data are estimates and may not be precise. Investing in biopharmaceutical companies involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Crinetics Pharmaceuticals Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2018-07-18 | Founder, President, CEO & Director Dr. R. Scott Struthers Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 437 | Website https://www.crinetics.com |
Full time employees 437 | Website https://www.crinetics.com | ||
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; SST3 Agonist program for the treatment for autosomal dominant polycystic kidney disease; and Radionetics for multiple solid-tumors, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.